ProCE Banner Activity

First-line CPX-351 Superior to 7 + 3 Induction in Older Patients With High-Risk AML

Slideset Download
Conference Coverage
Randomized phase III investigation of CPX-351 vs “7 + 3” induction identified a potential new standard of care for older patients with previously untreated high-risk AML.

Released: June 08, 2016

Expiration: June 07, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals